Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

PANCAID PANcreatic CAncer Initial Detection via liquid biopsy

Coordinator
Universitaetsklinikum Hamburg-Eppendorf, Germany
Runs
1 January 2023 to 31 December 2027
Status
Running
EU funding
€9.8m
Total cost
€9.8m
Partners
22 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101096309

What the project is doing

In the project's own words, from its summary on CORDIS.

Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will therefore develop a blood test for early detection of PDAC. Despite tremendous technological advances in Liquid Biopsy Diagnostics (LBx), this goal is very ambitious because small tumors release only minute amounts of cells or cellular products (e.g., DNA, RNA, protein, metabolites) into the circulation.

Thus, tests with a high sensitivity are required but increases in sensitivity are usually achieved on the expenses of reduced specificity which can lead to significant overdiagnosis leading to unnecessary stress for the individuals with a false-positive blood test and high costs for the health system. In PANCAID, we will therefore establish a blood test with high accuracy by analyzing large cohorts of patients with PDAC and its precursor lesions, individuals at risk to develop PDAC and appropriate age-matched control groups (healthy and non-cancer diseases frequent in the targeted population).

Ambitious objectives of PANCAID include (1) establishment of a unique resource of blood samples of early PDAC and risk groups (WP1); (2) Establishment of a breakthrough blood test for early diagnosis of PDAC (WP2); (3) Identification of the best composite biomarker panel by integrating multimodal features in an AI-assisted computational analysis; (4) Analysis of the socio-economic impact of early PDAC diagnosis (WP4); and (5) Definition of the ethics parameters relevant to early PDAC detection (WP5).

A robust multi-biomarker panel will be determined during the training period (year 1-3) and subsequently validated on bio-banked blood samples (year 4-5). Depending on the outcome of this comprehensive analysis, PANCAID will provide the design of a future prospective study for validation of the developed composite blood test in an international multi-center setting required to introduce LBx into screening programs for high-risk individuals.

This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.

Topics

Who is involved

OrganisationCityCountryRole
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyCoordinator
Medizinische Universitat GrazGrazAustriaParticipant
Pancreatic Cancer EuropeBruxelles / BrusselBelgiumParticipant
Christian-Albrechts-Universitaet Zu KielKielGermanyThird party
Concentris Research Management GmbHFurstenfeldbruckGermanyParticipant
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Universitatsklinikum HeidelbergHeidelbergGermanyParticipant
Universitatsklinikum Schleswig-HolsteinLübeckGermanyParticipant
Zava Deutschland GmbHHamburgGermanyParticipant
Zava Global GmbHHamburgGermanyParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y CajalMadridSpainParticipant
Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos IiiMadridSpainParticipant
Centre Hospitalier Universitaire MontpellierMontpellierFranceParticipant
Maccabi Sheirutei Briut FoundationTel AvivIsraelParticipant
The Hebrew University of JerusalemJerusalemIsraelParticipant
Collective Minds Radiology ABDanderydSwedenParticipant
Karolinska InstitutetStockholmSwedenParticipant
Region StockholmStockholmSwedenParticipant
Umea UniversitetUmeaSwedenParticipant
Uppsala UniversitetUppsalaSwedenParticipant
Queen Mary University of LondonLondonUnited KingdomAssociatedpartner
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI